A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.
Saved in:
| Title: | A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer. |
|---|---|
| Authors: | Zhang T; Duke Cancer Institute, Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina., Harrison MR; Duke Cancer Institute, Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina., O'Donnell PH; University of Chicago, Chicago, Illinois., Alva AS; University of Michigan Medical Center, Ann Arbor, Michigan., Hahn NM; Johns Hopkins University, Baltimore, Maryland., Appleman LJ; University of Pittsburgh, Pittsburgh, Pennsylvania., Cetnar J; Oregon Health and Science University Center for Health, Portland, Oregon., Burke JM; Rocky Mountain Cancer Centers, Aurora, Colorado., Fleming MT; Virginia Oncology Associates, Norfolk, Virginia., Milowsky MI; Lineberger Comprehensive Cancer Center, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina., Mortazavi A; Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Shore N; Carolina Urologic Research Center, Myrtle Beach, South Carolina., Sonpavde GP; Dana-Farber Cancer Institute, Boston, Massachusetts., Schmidt EV; Merck & Co, Inc, North Wales, Pennsylvania., Bitman B; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California., Munugalavadla V; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California., Izumi R; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California., Patel P; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California., Staats J; Division of Surgical Sciences, Department of Surgery, Duke University Medical Center, Durham, North Carolina., Chan C; Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina., Weinhold KJ; Division of Surgical Sciences, Department of Surgery, Duke University Medical Center, Durham, North Carolina., George DJ; Duke Cancer Institute, Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina.; Duke Clinical Research Institute, Durham, North Carolina. |
| Source: | Cancer [Cancer] 2020 Oct 15; Vol. 126 (20), pp. 4485-4497. Date of Electronic Publication: 2020 Aug 05. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1097-0142 |
|---|---|
| DOI: | 10.1002/cncr.33067 |
